New Healthtech VC Fund Launch: Shoni Health Ventures Affiliated with ARC Innovation at Sheba Medical Center
The Fund is Set to Invest in Promising Startups Specializing in Digital Health and Medical Devices and Bring them to Global Markets
Shoni Health Ventures, a healthtech fund affiliated with ARC Innovation at Sheba Medical Center, will invest in startups specializing in digital health and medical devices. The fund will invest in early-stage (pre-seed and seed stage) startups and will utilize its unique resources to support entrepreneurs in various aspects of their company’s growth. Shoni will create the ideal conditions for entrepreneurial success. The fund has already invested in five healthtech startups: Quant Health, AISAP, CoPilotMD, FeelBetter, and Append Medical.
Shoni Health Ventures is strategically and commercially tied to ARC Innovation at Sheba Medical Center, one of the world’s top hospitals. This strong alliance brings the portfolio companies extraordinary access to global partnerships, more than 25 years of medical data and medical personnel. Eran Lerer leads the fund as the CEO and Managing Partner and brings a wealth of experience in venture capital investments, business development, marketing and sales in digital health, medical devices and pharmaceuticals.
“Many healthtech startups around the world are struggling to attract early-stage investors.Consequently, many potential innovative solutions that could significantly improve global health remain unrealized,” said Eran Lerer, CEO & Managing Partner, Shoni Health Ventures. “We aim to bridge this gap, supporting healthtech startups in bringing their innovative solutions to market and make a global impact.”
“The digital health sector has seen considerable growth in recent years, and even with the recent slowing of the market, we believe that digital transformation is the only way forward in the long run,” said Prof. Eyal Zimlichman, Chief Transformation Officer and Chief Innovation Officer at Sheba Medical Center and Director and Founder of ARC Innovation. “With the latest advancements in artificial intelligence, bio-convergence, and other technologies, we are just beginning to see the impact of digital and smart solutions on the future of health. ARC Innovation is thrilled to announce the partnership with Shoni Health Ventures.”
Shoni Health Ventures fund was established by Dr. Ran Goshen and Sarah Greenberg. Dr. Goshen is an expert in gyneco-oncology and an entrepreneur in cancer-related innovations. He is also the founder of N1X10, serving as its hands-on chairman and chief physician. N1X10 is at the forefront of creating the first global network for cancer patients and specialists, introducing revolutionary support services. Previously, Ran led the life science investments at the VC firm Israel Seed Partners. He holds an MD from the Hadassah Medical School at the Hebrew University of Jerusalem, earned his board certification in Obstetrics and Gynecology from Hadassah Mount Scopus Hospital, was certified as a Gynecologic Oncologist at the University of Toronto, and holds a doctorate in cell biology from the Hebrew University through the Silberman Institute for Life Sciences.
Sarah Greenberg is a dynamic business and social entrepreneur. Her experience spans venture capital investments, corporate strategy, impact investments, along with roles in public and social sectors in the US, China, and Israel. Sarah made Aliyah to Israel in 2015, where she volunteered for service in the IDF. From 2018 to 2019, she held a role as the foreign relations advisor to the Israeli Prime Minister, tasked, among others, with writing his English speeches. In 2020, she launched an investment fund aimed at nurturing breakthrough technologies across a range of sectors. Currently, Sarah chairs the investment arm of the Seed the Dream Foundation, striving to foster social leadership and equal opportunities through education and empowering women. She holds a bachelor’s in economics from Yale University and two master’s degrees in business administration and public policy, both from Harvard University.